Chemical and Pharmaceutical Bulletin
Online ISSN : 1347-5223
Print ISSN : 0009-2363
ISSN-L : 0009-2363
Regular Articles
Improving Powder Flow Properties of a Direct Compression Formulation Using a Two-Step Glidant Mixing Process
Hidaka AbeShinichiro YasuiAya KuwataHirofumi Takeuchi
Author information
JOURNAL FREE ACCESS

2009 Volume 57 Issue 7 Pages 647-652

Details
Abstract
To improve powder flow of a high-dose direct compression formulation (drug content 30%), we compared a two-step operation for mixing glidants with a conventional one-step glidant mixing process. This two-step mixing operation was studied with two kinds of mixtures; an active pharmaceutical ingredient (API)-glidant combination and a direct compression excipient-glidant combination. The two-step operation permitted the selection of the optimum glidant type and concentration in each glidant-mixing procedure even though the formulation had different powder properties such as micronized API and enlarged direct compression vehicles, whereas the conventional approaches forced the selection of a certain glidant type and concentration at one-step mixing. The addition of 0.5% nonporous silica markedly improved API flow. In contrast, 1.0% porous silica was the appropriate glidant to enhance excipient flow at direct compression excipient-glidant mixing. The two-step operation dominantly enhanced powder flow when the appropriate API-glidant mixture and the suitable direct compression excipients-glidant mixture were blended compared to the one-step operation with its optimum glidant concentration. The results showed that the angle of repose was 43° and the critical orifice diameter was 10 mm in the two-step operation, whereas it was 47° and 16 mm in the one-step operation. The two-step operation of glidant mixing enhanced powder flow of the high-dose direct compression formulation compared with the one-step operation. The two-step operation eliminates the bottleneck of powder flow and allows direct compression to be more worth applying for formulation and process development trials.
Content from these authors
© 2009 The Pharmaceutical Society of Japan
Next article
feedback
Top